Bicalutamide for young women with PCOS and fatty liver
Treatments studied
Part of Digestive system clinical trials.
This trial tests a medicine called bicalutamide (an anti-androgen) to see if it can help young women with both PCOS and fatty liver disease (NASH). The goal is to find a new treatment option for these two conditions together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 42 years old.
- You have PCOS with high male hormone levels (hyperandrogenism).
- You have a fatty liver disease called NASH (confirmed by a liver biopsy or a special ultrasound).
- You do not drink more than 2 alcoholic drinks per day on average.
- You are not pregnant, planning pregnancy, or breastfeeding.
- You do not have uncontrolled diabetes or other serious liver diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how hormones (androgens) relate to fatty liver disease (MASH) in women, especially those with PCOS. It aims to understand why some women develop worse liver problems and might help find new ways to treat or prevent them.
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.